BREAST CANCER

Adam Brufsky, MD, PhD, FACP, discusses background and next steps of the phase 3 PALOMA-2 study which evaluated palbociclib plus letrozole in patients that identified as Black or Hispanic with advanced breast cancer.

The primary end point of progression-free survival was met in TROPION-Breast01, a phase 3 study of datopotamab deruxtecan for patients with hormone receptor-positive/HER2-negative breast cancer.

Treatment with datopotamab deruxtecan led to a statistically significant and clinically meaningful improvement in progression-free survival in patients with metastatic hormone receptor-positive breast cancer.

Findings from a recent analysis of the DESTINY-Breast04 trial demonstrate improvement in efficacy when trastuzumab deruxtecan monotherapy is used for patients with HER2-low metastatic breast cancer.

Adding pembrolizumab to chemotherapy reduced the risk for disease recurrence, progression, complications, or death compared with chemotherapy alone in the treatment of triple-negative breast cancer.

Extending abemaciclib with endocrine therapy for 2 years continues to lower the risk of invasive disease and distant relapse in hormone receptor-positive, HER2-negative breast cancer, as demonstrated in the 5-year efficacy findings from the monarchE trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, Laura Huppert, MD, and participants discussed treatment approaches for a patient HR-positive, HER2-negative breast cancer with liver and lung metastases who continues to progress on endocrine therapy and CDK4/6 inhibitors.

In the first article of a 2-part series, Aditya Bardia, MD, MPH, explains how recent survival outcomes with sacituzumab govitecan impressed physicians treating patients with metastatic breast cancer.

Sandra M. Swain, MD, FACP, FASCO, reviews clinical trial data and how they inform the evolving treatment landscape in HER2+ early breast cancer.

Chirag Shah, MD, discusses the challenges in predicting the risk of local recurrence in patients with ductal carcinoma in situ, and what led to the DCISionRT test.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, discussed with other physicians their experience with elacestrant in patients with estrogen receptor–positive, HER2-negative breast cancer. This is the second article based on this event.

At a live virtual event, Jane Lowe Meisel, MD, provided insights into the latest practice updates for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Rebecca A. Shatsky, MD, looks to the future of biomarker testing in metastatic breast cancer and offers advice to community oncologists.

A medical oncologist discusses challenges with conducting molecular testing and reviews clinical trials focused on biomarkers for patients with ER+/HER2- metastatic breast cancer.

A review of results from the EMERALD trial investigating elacestrant in patients with ESR1-mutated metastatic breast cancer.

Rebecca A. Shatsky, MD, reviews biomarker testing guideline recommendations for patients with breast cancer and discusses testing practices upon progression.

An expert on breast cancer provides clinical insights on liquid and tissue biopsies for patients with metastatic disease.

A medical oncologist discusses molecular biomarkers identified in patients with metastatic breast cancer and compares ESR1 with other genetic mutations.

Rebecca A. Shatsky, MD, provides an overview of ER+/HER2- metastatic breast cancer and discusses its incidence and prevalence.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, and participants discussed switching CDK4/6 inhibitors and continuing use beyond progression in patients with metastatic breast cancer. This is the first of 2 articles based on this event.

IDE161 now has 2 fast track designations from the FDA for patients with breast cancer and ovarian cancer. The agent continues to be evaluated in a first-in-human, phase 1 study for patients with advanced solid tumors.

Results from a new study could lead to the development of biomarkers for predicting treatment response and the implementation of strategies to address acquired resistance of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tiffany A. Traina, MD, reviewed data from the TROPiCS-02 and DESTINY-Breast04 and discussed using antibody-drug conjugates in patients with metastatic breast cancer.

Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.